Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection

E. Gane, Z. Ben Ari, L. Mollison, E. Zuckerman, R. Bruck, Y. Baruch, A. Y.M. Howe, J. Wahl, S. Bhanja, P. Hwang, Y. Zhao, M. N. Robertson

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection'. Together they form a unique fingerprint.

Medicine & Life Sciences